Stock listing
NASDAQ:TNGX Tango Therapeutics, Inc. Stock
Home listing (NASDAQ) of Tango Therapeutics, Inc.
Follow Tango Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TNGX
$21.73 USD -0.16 (-0.7%)
Close on Nov 20, 2026
- Day range
- $21.63 – $23.05 USDNov 20, 2026
- Volume
- 1.74M sharesNov 20, 2026
- Market cap
- $3.68B USDAt the close on Nov 20, 2026 · price × 169.5M shares outstanding
- 52-week range
- $8.30 – $34.39 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $80.18M USDMedian day 2.87M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TNGX · Home | $21.73 USD | -0.16 (-0.7%) | 1,740,329 | $22.11 | $23.05 | $21.63 | $21.89 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TNGX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $21.73 | -0.16 | -0.7% | $22.11 | $23.05 | $21.63 | 1,740,329 | |
| $21.89 | -0.22 | -1.0% | $22.03 | $22.36 | $21.27 | 2,746,141 | |
| $22.11 | -2.06 | -8.5% | $24.08 | $24.32 | $22.05 | 2,057,514 | |
| $24.17 | -1.33 | -5.2% | $24.85 | $25.87 | $24.15 | 1,580,684 | |
| $25.50 | +0.65 | +2.6% | $24.76 | $25.58 | $23.66 | 2,706,075 | |
| $24.85 | -0.88 | -3.4% | $25.33 | $25.37 | $23.61 | 3,488,265 | |
| $25.73 | +1.43 | +5.9% | $24.68 | $26.41 | $23.87 | 3,866,649 | |
| $24.30 | +1.56 | +6.9% | $22.74 | $24.65 | $22.38 | 4,560,772 | |
| $22.74 | +1.24 | +5.8% | $21.63 | $23.28 | $21.12 | 2,516,737 | |
| $21.50 | +0.63 | +3.0% | $20.74 | $22.11 | $20.74 | 2,129,301 | |
| $20.87 | -2.31 | -10.0% | $23.25 | $23.58 | $20.78 | 3,403,948 | |
| $23.18 | +0.01 | 0.0% | $24.16 | $24.75 | $22.67 | 2,464,255 | |
| $23.17 | +1.41 | +6.5% | $22.09 | $23.97 | $21.99 | 2,458,054 | |
| $21.76 | -0.96 | -4.2% | $22.65 | $23.31 | $21.72 | 3,681,587 | |
| $22.72 | +0.19 | +0.8% | $22.11 | $22.75 | $21.71 | 5,279,230 | |
| $22.53 | +0.30 | +1.3% | $22.36 | $23.58 | $22.36 | 3,369,953 | |
| $22.23 | -0.66 | -2.9% | $22.86 | $23.71 | $22.14 | 3,309,657 | |
| $22.89 | +0.695 | +3.1% | $22.02 | $23.50 | $21.81 | 3,322,765 | |
| $22.20 | -1.145 | -4.9% | $23.41 | $23.95 | $22.00 | 5,370,456 | |
| $23.34 | -4.59 | -16.4% | $25.54 | $25.94 | $22.68 | 15,852,900 | |
| $27.93 | +0.95 | +3.5% | $26.67 | $27.98 | $25.94 | 5,964,100 | |
| $26.98 | +1.73 | +6.9% | $25.55 | $27.60 | $25.35 | 5,557,300 | |
| $25.25 | +1.72 | +7.3% | $23.95 | $25.35 | $23.20 | 2,673,700 | |
| $23.53 | +1.49 | +6.8% | $22.49 | $23.86 | $22.36 | 1,870,800 | |
| $22.04 | -0.66 | -2.9% | $23.12 | $23.17 | $21.82 | 3,688,300 | |
| $22.70 | +0.51 | +2.3% | $22.27 | $22.96 | $21.79 | 2,903,900 | |
| $22.19 | -0.03 | -0.1% | $21.98 | $23.02 | $21.52 | 3,438,800 | |
| $22.22 | -1.95 | -8.1% | $23.85 | $24.11 | $21.85 | 9,619,100 | |
| $24.17 | +0.36 | +1.5% | $23.57 | $24.47 | $23.34 | 2,868,000 | |
| $23.81 | +1.24 | +5.5% | $22.60 | $24.12 | $22.44 | 3,098,800 | |
| $22.57 | +0.74 | +3.4% | $21.57 | $22.68 | $20.98 | 5,074,400 | |
| $21.83 | -0.07 | -0.3% | $21.64 | $22.46 | $21.38 | 3,392,800 | |
| $21.90 | -1.18 | -5.1% | $23.16 | $23.16 | $21.36 | 4,351,000 | |
| $23.08 | -0.16 | -0.7% | $23.29 | $23.56 | $22.25 | 1,943,900 | |
| $23.24 | -1.21 | -4.9% | $25.09 | $25.09 | $23.09 | 5,253,600 | |
| $24.45 | -0.50 | -2.0% | $24.90 | $25.43 | $23.95 | 2,910,300 | |
| $24.95 | +0.53 | +2.2% | $24.64 | $25.41 | $23.82 | 3,660,500 | |
| $24.42 | +0.12 | +0.5% | $24.32 | $24.80 | $23.18 | 2,992,200 | |
| $24.30 | -0.62 | -2.5% | $24.92 | $24.92 | $23.70 | 2,413,400 | |
| $24.92 | +0.29 | +1.2% | $24.95 | $25.38 | $24.08 | 3,255,000 | |
| $24.63 | +0.18 | +0.7% | $23.99 | $24.83 | $23.50 | 2,290,600 | |
| $24.45 | -1.08 | -4.2% | $25.40 | $25.92 | $24.06 | 4,957,100 | |
| $25.53 | +3.20 | +14.3% | $22.33 | $25.75 | $22.25 | 6,968,700 | |
| $22.33 | +0.58 | +2.7% | $21.90 | $22.74 | $21.63 | 2,555,300 | |
| $21.75 | -1.74 | -7.4% | $23.33 | $23.55 | $21.72 | 6,242,500 | |
| $23.49 | +0.14 | +0.6% | $23.79 | $24.63 | $23.41 | 1,721,900 | |
| $23.35 | -0.54 | -2.3% | $24.17 | $24.39 | $23.00 | 2,835,500 | |
| $23.89 | -0.65 | -2.6% | $24.55 | $24.55 | $23.59 | 1,791,000 | |
| $24.54 | +0.76 | +3.2% | $23.98 | $24.99 | $23.44 | 2,010,900 | |
| $23.78 | +0.41 | +1.8% | $23.72 | $24.63 | $23.19 | 2,279,300 | |
| $23.37 | -0.63 | -2.6% | $23.16 | $24.30 | $23.16 | 3,437,300 | |
| $24.00 | +1.30 | +5.7% | $22.99 | $25.52 | $22.63 | 4,664,500 | |
| $22.70 | +0.18 | +0.8% | $22.50 | $23.08 | $22.26 | 2,424,800 | |
| $22.52 | -0.24 | -1.1% | $22.48 | $22.94 | $22.29 | 1,457,400 | |
| $22.76 | +0.44 | +2.0% | $22.50 | $22.79 | $22.13 | 1,343,700 | |
| $22.32 | -0.03 | -0.1% | $22.62 | $23.12 | $21.64 | 1,916,400 | |
| $22.35 | -0.49 | -2.1% | $22.60 | $23.06 | $22.07 | 1,544,300 | |
| $22.84 | -0.50 | -2.1% | $23.28 | $23.50 | $22.61 | 1,850,100 | |
| $23.34 | -1.94 | -7.7% | $24.93 | $25.09 | $23.28 | 1,999,000 | |
| $25.28 | -0.19 | -0.7% | $25.39 | $26.85 | $25.24 | 2,037,400 | |
| $25.47 | +0.70 | +2.8% | $24.65 | $27.00 | $24.26 | 3,173,900 | |
| $24.77 | +0.26 | +1.1% | $25.04 | $25.61 | $24.35 | 2,283,248 | |
| $24.51 | +0.63 | +2.6% | $23.60 | $24.68 | $22.91 | 2,088,761 | |
| $23.88 | +0.37 | +1.6% | $23.95 | $24.36 | $23.48 | 2,488,700 | |
| $23.51 | -1.69 | -6.7% | $25.51 | $25.67 | $23.15 | 2,064,600 |
- Ticker
- NASDAQ:TNGX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Latest deck · Oct 23, 2026
PDAC Investor Presentation (October 2026)
Conference · 35 slides
Latest news
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Nov 9, 2026
Closed $22.74 (+5.8%) on Nov 9, 2026
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Nov 4, 2026
Closed $23.18 (0.0%) on Nov 4, 2026
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
Nov 3, 2026
Closed $23.17 (+6.5%) on Nov 3, 2026
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
Oct 23, 2026
Closed $23.34 (-16.4%) on Oct 23, 2026
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Oct 16, 2026
Closed $22.04 (-2.9%) on Oct 16, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2026
Closed $22.52 (-1.1%) on Sep 4, 2026
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Sep 1, 2026
Closed $22.35 (-2.1%) on Sep 1, 2026
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Aug 11, 2026
Closed $26.34 (-4.8%) on Aug 11, 2026
Tango Therapeutics Announces Executive Chair Transition
Aug 6, 2026
Closed $27.07 (-6.7%) on Aug 7, 2026
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Jun 22, 2026
Closed $28.39 (-0.4%) on Jun 23, 2026
Tango Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 92 in all · newest Nov 9, 2026 · oldest 2021
- Decks
- 16 decks · latest Oct 23, 2026
Where Tango Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TNGX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TNGX | BOATS | United States | USD |
Valuation
Price/book 3.8× against a median of 4.0×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.74B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.41
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics, Inc. · NASDAQ:TNGX | US$3.68B | US$2.74B | n/a | n/a | n/a | 3.8× | n/a | 0.0× | 1.41 |
| Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192 | US$3.90B | US$3.18B | 7.5× | 4.3× | n/a | 5.2× | 69.3% | 0.1× | n/a |
| Definium Therapeutics, Inc. · NASDAQ:DFTX | US$3.88B | US$2.87B | n/a | n/a | n/a | 4.0× | n/a | 0.0× | 1.14 |
| CRISPR Therapeutics AG · NASDAQ:CRSP | US$3.79B | US$2.11B | n/a | 83.7× | n/a | 2.3× | n/a | 0.4× | 1.64 |
| Xenon Pharmaceuticals Inc. · NASDAQ:XENE | US$3.64B | US$2.70B | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 0.80 |
| Relay Therapeutics, Inc. · NASDAQ:RLAY | US$3.56B | US$2.74B | n/a | 265× | n/a | 4.3× | n/a | 0.0× | 1.48 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336 | US$3.56B | US$3.42B | 7.6× | 5.1× | n/a | 2.7× | 69.9% | 0.0× | n/a |
| Enliven Therapeutics, Inc. · NASDAQ:ELVN | US$3.42B | US$2.54B | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 0.89 |
| Disc Medicine, Inc. · NASDAQ:IRON | US$3.42B | US$2.80B | n/a | n/a | n/a | 5.7× | n/a | 0.1× | 0.94 |
| Viridian Therapeutics, Inc. · NASDAQ:VRDN | US$3.40B | US$2.69B | n/a | 102× | n/a | 5.9× | n/a | 0.4× | 1.00 |
| Parabilis Medicines, Inc. · NASDAQ:PBLS | US$3.39B | US$2.53B | n/a | n/a | n/a | 3.4× | n/a | 0.0× | n/a |
| Median of the others | US$3.56B | US$2.72B | 7.6× | 83.7× | 4.0× | 69.6% | 0.0× | 1.00 |
Forecasts
11 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 47.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.45 · 13 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Malte Peters | President & Chief Executive Officer, Tango Therapeutics |
| Robert Azelby | Chairman; Former President and CEO, Eliem Therapeutics, Inc. |
| Matthew Gall | Chief Financial Officer |
| Sung Lee | Executive Vice President and Chief Financial Officer, Cytokinetics |
| Adam Crystal | President, Research & Development |
| Mace Rothenberg | President and Executive Director, Museum of Medicine and Biomedical Discovery |
| Julie Fogarty | SVP, General Counsel |
| Janice Kapty | SVP, Corporate Strategy and Project Leadership |
| Lesley Ann Calhoun | EVP, Aligos Therapeutics |
| Fatma Ocak | Chief Commercialization Officer |
| Julie Carretero | Chief Human Resources Officer |
| Philippe Serrano | Chief Regulatory Officer |
| Yen-Ching Chua | Chief Development Operations Officer |
Board
| Director | Role |
|---|---|
| Robert Azelby | Chairman; Former President and CEO, Eliem Therapeutics, Inc. |
| Mace Rothenberg | President and Executive Director, Museum of Medicine and Biomedical Discovery |
| Malte Peters | President & Chief Executive Officer, Tango Therapeutics |
| Sung Lee | Executive Vice President and Chief Financial Officer, Cytokinetics |
Events
- Next results
- Mar 4, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +5.8% |
| Q2 2026 | Aug 11, 2026 · Before open | −4.8% |
| Q1 2026 | May 13, 2026 | +5.8% |
| Q4 2025 | Mar 5, 2026 · Before open | +36.3% |
| Q3 2025 | Nov 4, 2025 · Before open | 0.0% |
| Q2 2025 | Aug 5, 2025 · Before open | +4.9% |
| Q1 2025 | May 12, 2025 · Before open | +14.9% |
| Q4 2024 | Mar 17, 2025 · Before open | 0.0% |
| Q3 2024 | Nov 6, 2024 · Before open | −37.5% |
| Q2 2024 | Aug 7, 2024 · Before open | −3.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | +0.8% |
| Q4 2023 | Mar 18, 2024 · Before open | −7.1% |
| Q3 2023 | Nov 8, 2023 · Before open | +3.8% |
| Q2 2023 | Aug 7, 2023 · Before open | +1.2% |
| Q1 2023 | May 9, 2023 · Before open | +6.4% |
| Q4 2022 | Mar 27, 2023 · Before open | −9.3% |
| Q3 2022 | Nov 10, 2022 · Before open | −5.3% |
| Q2 2022 | Aug 10, 2022 · Before open | +22.4% |
| Q1 2022 | May 11, 2022 · Before open | −7.6% |
| Q4 2021 | Mar 28, 2022 · Before open | +0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| PDAC Investor Presentation (October 2026) | Conference | 35 slides | Oct 23, 2026 |
| PDAC Investor Presentation (October 2026) | Conference | 35 slides | Oct 23, 2026 |
| Investor Presentation (August 2026) | Investor deck | 36 slides | August 2026 |
| Technical Presentation (June 2026) | Technical | 31 slides | Jun 8, 2026 |
| JP Morgan Healthcare Conference 2026 | Conference | 24 slides | Jan 8, 2026 |
| AACR 2026 | Conference | 22 slides | 2026 |
| Technical Presentation (November 2025) | Technical | 18 slides | Nov 4, 2025 |
| Technical Presentation (October 2025) | Technical | 26 slides | Oct 30, 2025 |
| Corporate Update (October 2025) | Corporate update | 20 slides | Oct 23, 2025 |
| Botton Champalimaud International Pancreatic Cancer Conference 2025 | Conference | 16 slides | October 2025 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2025) | Investor deck | 34 slides | May 2025 |
| Investor Presentation (January 2025) | Investor deck | 40 slides | Jan 13, 2025 |
| SPAC Merger (April 2021) | SPAC merger | 14 slides | Apr 14, 2021 |
| SPAC Merger (April 2021) | SPAC merger | 14 slides | April 2021 |
| Technical Presentation (2021) | Technical | 9 slides | 2021 |
| Technical Presentation (2021) | Technical | 7 slides | 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$600M · US$30 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Cantor (co-lead), Stifel (co-lead) | Jun 10, 2026 |
| Public offering of common stock and pre-funded warrants Announced: about US$210M · US$8.66 a share · Leerink Partners +1 Dealers: Leerink Partners (co-lead), Cantor (co-lead) Buyers: Farallon Capital Management; TCGX; Balyasny Asset Management; Woodline Partners LP; Invus; Adage Capital Management LP; Boxer Capital Management; Logos Capital; Nantahala Capital; accounts advised by T. Rowe Price Investment Management, Inc. | Oct 23, 2025 |
| Private placement of common stock Announced: about US$15M · US$8.66 a share Buyers: Nextech (led the PIPE) | Oct 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as BCTG Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a share on Sep 2, 2020.
- Price
- US$10.00 a share
- Shares offered
- 14,500,000 shares of common stock
- Offering size
- US$145 million
- Underwriters' option
- Up to 2,175,000 more shares
- Listing
- BCTG on the Nasdaq Capital Market
- Underwriter
- SVB Leerink
- Shares delivered
- On or about Sep 8, 2020
Steps
| Step | When |
|---|---|
| Filed publicly | Jul 30, 2020 |
| Amended once | Aug 31, 2020 |
| Shares registered with an exchange | Sep 2, 2020 |
| Declared effective by the SEC | Sep 2, 2020 |
| Final prospectus, with the price | Sep 4, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 4, 2020 |
| CERT · Exchange's certificate of listing | Sep 3, 2020 |
| EFFECT · Notice that a registration is effective | Sep 2, 2020 |
| S-1MEF · Registration of more shares for the same offering | Sep 2, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 2, 2020 |
| S-1/A · Registration statement, amended | Aug 31, 2020 |
| S-1 · Registration statement | Jul 30, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 4, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 62.4M | 42.1M | 36.5M | 24.9M | 37.0M | 7.66M | 24.6M |
| Cost of revenue | 2.28M | 2.50M | 115.2M | 4.03M | 1.97M | 1.63M | 32.3M |
| Gross profit | 60.1M | 42.1M | 36.5M | 24.9M | 37.0M | 6.03M | -7.63M |
| Research and development | 132.2M | 143.9M | 115.2M | 105.9M | 77.6M | 50.0M | 32.3M |
| Selling, general and administrative | 41.5M | 43.7M | 35.5M | 30.0M | 17.6M | 9.87M | 7.54M |
| Operating income | -111.3M | -145.6M | -114.2M | -111.1M | -58.2M | -52.2M | -15.2M |
| Depreciation and amortization | 2.28M | 2.50M | 2.42M | 1.61M | 897.0K | 718.0K | 643.0K |
| EBITDA | -109.0M | -143.1M | -111.8M | -109.5M | -57.3M | -51.5M | -14.5M |
| Interest expense | 2.95M | 1.14M | 0 | 0 | |||
| Income before tax | -101.6M | -130.1M | -101.6M | -108.1M | -57.9M | -52.0M | -14.1M |
| Income tax | 4.00K | 208.0K | 134.0K | 54.0K | 292.0K | 0 | |
| Net income | -101.6M | -130.3M | -101.7M | -108.2M | -58.2M | -52.0M | -14.1M |
| Earnings per share, basic | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 | -0.16 |
| Earnings per share, diluted | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 112.3M | 69.5M | 66.4M | 60.0M | 142.7M | 28.4M | 22.9M |
| Short-term investments | 230.9M | 188.4M | 270.5M | 306.2M | 342.5M | 161.9M | 17.5M |
| Receivables | 0 | 2.00M | 2.00M | 2.00M | |||
| Inventory | 567.0K | 567.0K | |||||
| Current assets | 353.8M | 266.3M | 346.5M | 375.3M | 492.3M | 193.6M | 41.7M |
| Property, plant and equipment | 6.87M | 8.10M | 9.91M | 10.9M | 4.83M | 3.82M | 11.8M |
| Total assets | 398.7M | 316.5M | 402.6M | 436.5M | 500.2M | 207.3M | 55.8M |
| Accounts payable | 1.18M | 1.60M | 2.79M | 4.45M | 3.23M | 1.84M | 670.0K |
| Current liabilities | 21.7M | 38.2M | 45.9M | 55.5M | 40.7M | 40.9M | 25.9M |
| Total debt | 33.6M | 36.5M | 38.9M | 41.1M | 1.50M | 7.88M | 8.54M |
| Total liabilities | 52.5M | 117.0M | 149.5M | 187.0M | 155.4M | 168.7M | 47.9M |
| Shareholders' equity | 346.2M | 199.5M | 253.1M | 249.5M | 344.7M | 38.6M | 7.91M |
| Shares outstanding | 135.9M | 107.7M | 102.2M | 88.2M | 87.6M | 40.4M | 87.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -138.9M | -131.5M | -118.0M | -109.1M | -59.5M | 70.1M | -24.8M |
| Capital spending | -1.05M | -754.0K | -1.53M | -7.69M | -1.84M | -1.11M | -1.82M |
| Free cash flow | -139.9M | -132.3M | -119.5M | -116.8M | -61.4M | 69.0M | -26.6M |
| Cash from investing | -40.9M | 86.1M | 41.4M | 26.4M | -183.4M | -145.5M | 848.0K |
| Cash from financing | 222.5M | 47.7M | 82.4M | 1.61M | 357.3M | 80.9M | 11.0M |
| Share buybacks | 31.0M | ||||||
| Change in cash | 42.7M | 2.29M | 5.85M | -81.1M | 114.4M | 5.49M | 25.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 11, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Aug 7, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 6, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 10, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 10, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Jun 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 8, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 8, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 21, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 21, 2025 | Material contract | SEC |
| S-3ASR · Registration statement | Nov 21, 2025 | Offer document | SEC |
| S-3 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| D | Oct 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 24, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Oct 23, 2025 | Other filings | SEC |
| FWP · Free writing prospectus | Oct 23, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 23, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 25, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 22, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 20, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 19, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| DEFR14A | Apr 23, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 28, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 25, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 22, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Oct 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 22, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 16, 2024 | Other filings | SEC |
This page holds 200 of 432 filings. Open Filings
Cap table
Built by 6ix from Tango Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 169,455,160
- Fully diluted
- 169,455,160
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 169,455,160 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 169,455,160 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Azelby Other companies: Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Cardinal Health, Inc. (Director · Since at least Mar 1, 2024); ADC Therapeutics SA (Director · Since at least Jan 2, 2024); Aduro Biotech Inc (Director · Apr 10, 2023 – Aug 11, 2023 · Past); Climb Bio, Inc. (President & CEO, Director · Aug 9, 2021 – Oct 31, 2022 · Past); Immunomedics Inc (Director · Feb 26, 2020 – Oct 23, 2020 · Past); Clovis Oncology Inc (Director · Oct 11, 2018 – Jun 10, 2021 · Past); Alder BioPharmaceuticals Inc (President and CEO, Director · Jun 13, 2018 – Oct 22, 2019 · Past); Cascadian Therapeutics Inc (Director · Mar 31, 2017 – Mar 9, 2018 · Past); Juno Therapeutics Inc (EVP & Chief Commercial Officer · Nov 1, 2015 – Mar 5, 2018 · Past) | Chairman; Former President and CEO, Eliem Therapeutics, Inc. · Since at least Jun 19, 2026 |
| Richard Heyman Other companies: Enliven Therapeutics, Inc. (Director · Since at least Feb 23, 2023); PMV Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2020); ORIC Pharmaceuticals, Inc. (Chairman · Since at least Apr 23, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Gritstone bio, Inc. (Director · Sep 27, 2018 – Jun 17, 2022 · Past) | Director · Sep 2, 2020 – Sep 2, 2020 · Past |
| Daniella Beckman Other companies: Upstream Bio, Inc. (Member, Board of Directors · Since at least Oct 10, 2024); Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past) | Chief Financial Officer · Since at least Aug 10, 2021 |
| Alexis Borisy Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Blueprint Medicines Corp (Director · Since at least Jun 18, 2025); Relay Therapeutics, Inc. (Director · Since at least Jun 6, 2025) | Director · Since at least Jun 5, 2025 |
| Charles Baum Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Jun 22, 2023); PMV Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2021); Poseida Therapeutics Inc (Director · May 16, 2022 – Jan 8, 2025 · Past); Immunomedics Inc (Director · Feb 23, 2019 – Oct 23, 2020 · Past) | Director · Sep 2, 2020 – Sep 2, 2020 · Past |
| Barbara Weber Other companies: Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); OPY Acquisition I Corp (Director · Oct 26, 2021 – Oct 26, 2021 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Oct 8, 2024 · Past) | Director, Executive Chair, Director · Since at least Aug 10, 2021 |
| Sung Lee Other companies: Cytokinetics, Incorporated (EVP, Chief Financial Officer · Since at least Apr 26, 2024); Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Mar 27, 2023 – Mar 27, 2024 · Past); Sangamo Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 31, 2019 – Nov 25, 2020 · Past) | Executive Vice President and Chief Financial Officer, Cytokinetics · Since at least Jan 2, 2026 |
| Aaron I Davis Other companies: Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jun 11, 2024 · Past) | Director · Jun 8, 2022 – Aug 11, 2023 · Past |
| Matthew Gall Other companies: Kalaris Therapeutics, Inc. (Chief Financial Officer · Since at least Nov 3, 2025); Iteos Therapeutics Inc (Chief Financial Officer · Since at least Jul 23, 2020) | Chief Financial Officer · Since at least Apr 15, 2026 |
| Adam Crystal Other companies: C4 Therapeutics, Inc. (Chief Medical Officer · May 25, 2022 – Jan 30, 2023 · Past) | President, Research & Development · Since at least Feb 27, 2023 |
All 27 people
| Person | Seat |
|---|---|
| Joseph Lewis Other companies: Inseego Corp. (Director · Aug 9, 2019 – Aug 9, 2019 · Past) | Director · Aug 11, 2023 – Aug 11, 2023 · Past |
| Mace Rothenberg Other companies: Surrozen, Inc. (Director · Since at least Aug 11, 2021) | Director · Since at least Aug 10, 2021 |
| Aaron Weitzman | Chief Medical Officer · Dec 1, 2022 – Dec 1, 2022 · Past |
| Alan Huang | Chief Scientific Officer · Aug 10, 2021 – Mar 1, 2023 · Past |
| Douglas Barry | General Counsel · Mar 1, 2023 – Feb 4, 2025 · Past |
| Fatma Ocak | Chief Commercialization Officer · Since at least Aug 11, 2026 |
| Janice Kapty | SVP, Corporate Strategy and Project Leadership · Since at least Apr 15, 2026 |
| Jessica Newcomb | Principal Accounting Officer · Since at least Sep 22, 2026 |
| John B Ketchum | Director · Since at least Aug 29, 2023 |
| Julie Carretero | Chief Human Resources Officer · Since at least Nov 4, 2026 |
| Julie Fogarty | SVP, General Counsel · Since at least Nov 4, 2026 |
| Kanishka Pothula | Director · Nov 6, 2023 – Nov 6, 2023 · Past |
| Lesley Ann Calhoun | EVP, Aligos Therapeutics · Since at least Jun 8, 2026 |
| Malte Peters | President & Chief Executive Officer, Tango Therapeutics · Since at least Nov 3, 2026 |
| Marc Rudoltz | Chief Medical Officer · Oct 18, 2021 – Nov 1, 2021 · Past |
| Philippe Serrano | Chief Regulatory Officer · Since at least Mar 5, 2026 |
| Yen-Ching Chua | Chief Development Operations Officer · Since at least Apr 15, 2026 |
Log in to ask 6ix AI your own questions about Tango Therapeutics, Inc.